Multiple roles of arsenic compounds in phase separation and membraneless organelles formation determine their therapeutic efficacy in tumors

IF 6.1 1区 医学 Q1 PHARMACOLOGY & PHARMACY Journal of Pharmaceutical Analysis Pub Date : 2024-02-24 DOI:10.1016/j.jpha.2024.02.011
Meiyu Qu, Qiangqiang He, Hangyang Bao, Xing Ji, Tingyu Shen, Muhammad Qasim Barkat, Ximei Wu, Ling-Hui Zeng
{"title":"Multiple roles of arsenic compounds in phase separation and membraneless organelles formation determine their therapeutic efficacy in tumors","authors":"Meiyu Qu, Qiangqiang He, Hangyang Bao, Xing Ji, Tingyu Shen, Muhammad Qasim Barkat, Ximei Wu, Ling-Hui Zeng","doi":"10.1016/j.jpha.2024.02.011","DOIUrl":null,"url":null,"abstract":"Arsenic compounds are widely used for the therapeutic intervention of multiple diseases. Ancient pharmacologists discovered the medicinal utility of such highly toxic substances, and modern pharmacologists have further recognized the specific active ingredients in human diseases. In particular, Arsenic trioxide (ATO), as a main component, has therapeutic effects on various tumors (including leukemia, hepatocellular carcinoma, lung cancer, etc.). However, its toxicity limits its efficacy, and how to control its toxicity has been an important issue. Interestingly, recently emerging evidence has pointed out the pivotal roles of arsenic compounds in phase separation and membraneless organelles formation, which may decide their toxicity and therapeutic efficacy. Here, we summarized the arsenic compounds-regulating phase separation and membraneless organelles formation. We further hypothesize their potential involvement in the therapy and toxicity of arsenic compounds, highlighting potential mechanisms underlying the clinical application of arsenic compounds.","PeriodicalId":16737,"journal":{"name":"Journal of Pharmaceutical Analysis","volume":"30 1","pages":""},"PeriodicalIF":6.1000,"publicationDate":"2024-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Analysis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jpha.2024.02.011","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Arsenic compounds are widely used for the therapeutic intervention of multiple diseases. Ancient pharmacologists discovered the medicinal utility of such highly toxic substances, and modern pharmacologists have further recognized the specific active ingredients in human diseases. In particular, Arsenic trioxide (ATO), as a main component, has therapeutic effects on various tumors (including leukemia, hepatocellular carcinoma, lung cancer, etc.). However, its toxicity limits its efficacy, and how to control its toxicity has been an important issue. Interestingly, recently emerging evidence has pointed out the pivotal roles of arsenic compounds in phase separation and membraneless organelles formation, which may decide their toxicity and therapeutic efficacy. Here, we summarized the arsenic compounds-regulating phase separation and membraneless organelles formation. We further hypothesize their potential involvement in the therapy and toxicity of arsenic compounds, highlighting potential mechanisms underlying the clinical application of arsenic compounds.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
砷化合物在相分离和无膜细胞器形成中的多重作用决定了其对肿瘤的疗效
砷化合物被广泛用于多种疾病的治疗干预。古代药理学家发现了这种剧毒物质的药用价值,现代药理学家则进一步认识到其在人类疾病中的特殊活性成分。其中,三氧化二砷(ATO)作为一种主要成分,对多种肿瘤(包括白血病、肝细胞癌、肺癌等)具有治疗作用。然而,三氧化二砷的毒性限制了其疗效,如何控制其毒性一直是一个重要问题。有趣的是,最近新出现的证据指出,砷化合物在相分离和无膜细胞器形成中起着关键作用,这可能会决定其毒性和疗效。在此,我们总结了调节相分离和无膜细胞器形成的砷化合物。我们进一步假设了它们在砷化合物治疗和毒性中的潜在参与,强调了砷化合物临床应用的潜在机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Pharmaceutical Analysis
Journal of Pharmaceutical Analysis Chemistry-Electrochemistry
CiteScore
16.20
自引率
2.30%
发文量
674
审稿时长
22 weeks
期刊介绍: The Journal of Pharmaceutical Analysis (JPA), established in 2011, serves as the official publication of Xi'an Jiaotong University. JPA is a monthly, peer-reviewed, open-access journal dedicated to disseminating noteworthy original research articles, review papers, short communications, news, research highlights, and editorials in the realm of Pharmacy Analysis. Encompassing a wide spectrum of topics, including Pharmaceutical Analysis, Analytical Techniques and Methods, Pharmacology, Metabolism, Drug Delivery, Cellular Imaging & Analysis, Natural Products, and Biosensing, JPA provides a comprehensive platform for scholarly discourse and innovation in the field.
期刊最新文献
Hepatic protein phosphatase 1 regulatory subunit 3G alleviates obesity and liver steatosis by regulating the gut microbiota and bile acid metabolism Retraction notice to “A DNA-based nanocarrier for efficient cancer therapy” [J. Pharm. Anal. 11 (2021) 330–339] Mapping conformational changes on bispecific antigen-binding biotherapeutic by covalent labeling and mass spectrometry Medcheck: a novel software for automatic de-formulation of traditional Chinese medicine (TCM) prescriptions by liquid chromatography-mass spectrometry 17β-Estradiol, through activating the G protein-coupled estrogen receptor, exacerbates the complication of benign prostate hyperplasia in type 2 diabetes mellitus patients by inducing prostate proliferation
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1